Trial Profile
A clinical trial of Ampligen (rintatolimod) for first line treatment of non-small cell lung cancer (NSCLC) with standard of care including pembrolizumab
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Rintatolimod (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Dec 2018 New trial record
- 15 Nov 2018 According to a Hemispherx Biopharma media release, Dr. V. Ernani, PI, the University of Nebraska Medical Center is currently working on the study design and budget details of this trial.